FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:426-428 August 8, 1996 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

The clinical complications of sickle cell anemia reflect the vascular damage caused by the abnormal red cells. Filled with hemoglobin S, sickle red cells obstruct and injure vessels when the abnormal hemoglobin polymerizes, is denatured, and releases toxic oxidants. The process insidiously affects vulnerable vascular beds in the spleen, brain, lung, kidney, eye, and heart. Except for the spleen and brain, where the complications may have a developmental component and arise in childhood, the compromise of most organs takes decades to develop. About 20 percent of deaths in sickle cell anemia occur in patients with chronic organ failure. The distressing, . . . [Full Text of this Article]

Recommended Reading

This article has been cited by other articles:

• Kean, L. S., Durham, M. M., Adams, A. B., Hsu, L. L., Perry, J. R., Dillehay, D., Pearson, T. C., Waller, E. K., Larsen, C. P., Archer, D. R. (2002). A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation. Blood 99: 1840-1849 [Abstract] [Full Text]  
• Orringer, E. P., Casella, J. F., Ataga, K. I., Koshy, M., Adams-Graves, P., Luchtman-Jones, L., Wun, T., Watanabe, M., Shafer, F., Kutlar, A., Abboud, M., Steinberg, M., Adler, B., Swerdlow, P., Terregino, C., Saccente, S., Files, B., Ballas, S., Brown, R., Wojtowicz-Praga, S., Grindel, J. M. (2001). Purified Poloxamer 188 for Treatment of Acute Vaso-occlusive Crisis of Sickle Cell Disease: A Randomized Controlled Trial. JAMA 286: 2099-2106 [Abstract] [Full Text]  
• Sullivan, K. M., Parkman, R., Walters, M. C. (2000). Bone Marrow Transplantation for Non-Malignant Disease. ASH Education Book 2000: 319-338 [Abstract] [Full Text]  
• Bunn, H. F. (1997). Pathogenesis and Treatment of Sickle Cell Disease. NEJM 337: 762-769 [Full Text]  
• Adams-Graves, P., Kedar, A., Koshy, M., Steinberg, M., Veith, R., Ward, D., Crawford, R., Edwards, S., Bustrack, J., Emanuele, M. (1997). RheothRx (Poloxamer 188) Injection for the Acute Painful Episode of Sickle Cell Disease: A Pilot Study. Blood 90: 2041-2046 [Abstract] [Full Text]  
• (1996). BONE MARROW TRANSPLANTATION FOR SICKLE CELL DISEASE. JWatch General 1996: 1-1 [Full Text]